SCHEMBL9040622

SCHEMBL9040622

FC(F)(F)c1nnc2cnc3cc(Cl)c(Cl)cc3n12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
CYP1A2 P05177 5/20 0.35
LMNA P02545 2/20 0.35
PAX8 Q06710 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
NPC1 O15118 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35
PIK3CB P42338 3/20 0.33
PRKDC P78527 3/20 0.33
ATM Q13315 2/20 0.32
ATR Q13535 2/20 0.32
ATRIP Q8WXE1 2/20 0.32
PDE2A O00408 1/20 0.32
MEN1 O00255 1/20 0.32
HPGD P15428 1/20 0.32
PPARG P37231 1/20 0.32
KMT2A Q03164 1/20 0.32
NCOA2 Q15596 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9037537 0.76 BRD4 (0.37) PIK3CBPRKDCATMATRATRIP
SCHEMBL9036947 0.73 POLB (0.46)
SCHEMBL9036533 0.71 ABL1 (0.44) ALDH1A1LMNANPSR1NPC1RAB9A
SCHEMBL9036696 0.71 GRIN2D (0.46) LMNAPIK3CBPRKDCATMATR
SCHEMBL9037233 0.69 AGTR1 (0.40) LMNAPDE2A
SCHEMBL11867415 0.64 NOTUM (0.37) ALDH1A1RAB9A
SCHEMBL9038736 0.62 KDM4E (0.47) ALDH1A1NPSR1NPC1RAB9AMEN1
SCHEMBL20190553 0.62 CYP1A2 (0.49) ALDH1A1CYP1A2SMN1; SMN2
SCHEMBL14054039 0.62 PDE2A (0.45) ALDH1A1CYP1A2LMNAPIK3CBPRKDC
SCHEMBL5935860 0.61 ALDH1A1 (0.36) ALDH1A1CYP1A2PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0518530-B1 Improvements in or relating to excitatory amino acid receptor antagonists LILLY CO ELI (US) 1996-10-09 EP disclosed
US-5196421-A Treatment of neurological disorders ELI LILLY AND COMPANY (US) 1993-03-23 US disclosed
EP-0518530-A2 Improvements in or relating to excitatory amino acid receptor antagonists ELI LILLY AND COMPANY (US) 1992-12-16 EP disclosed
US-5153196-A Administering for reduction of neurotransmission in nervous system disorders ELI LILLY AND COMPANY (US) 1992-10-06 US disclosed